ASH 2024 Preview for Integrative Care: The Show and After Show
CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
The American Society of Hematology (ASH) Annual Meeting and Exposition will highlight key developments in hematology and oncology, with a focus on novel therapies in the space, data to support upcoming FDA approvals, and more.
In the next episode of The Show and After Show, co-hosts Kristie L. Kahl and Andrew Svonavec offer a glimpse at some of the presentations guaranteed to spark one’s curiosity, spur debate, and enhance the field even further. Some key highlights include:
Novel Therapies for Multiple Myeloma
- Daratumumab (Darzalex) monotherapy: The phase 3 study evaluating daratumumab monotherapy in high-risk smoldering multiple myeloma has generated significant interest. The potential for improved survival outcomes with this targeted therapy could reshape treatment paradigms.
- Simplified response assessment: A focus on reducing the burden of disease monitoring has led to the exploration of urine-free International Myeloma Working Group (IMWG) response criteria. This approach may streamline patient care and enhance adherence to treatment plans.
Anticipated FDA Approvals in 2025
- Acalabrutinib (Calquence) in mantle cell lymphoma (MCL): The FDA is set to review the approval of acalabrutinib with bendamustine or rituximab (Rituxan) for previously untreated MCL, based on data from the phase 3 ECHO trial (NCT02972840).
- Asciminib (Scemblix) in chronic phase chronic myelogenous leukemia (CML-CP): The FDA is also reviewing the priority review of asciminib for newly diagnosed CML-CP. This tyrosine kinase inhibitor has shown favorable safety and tolerability profiles, making it a potential new treatment option for patients.
Emerging Trends in Blood Cancer
- CAR T-cell therapies: Continued advancements in CAR T-cell therapy are expected to revolutionize the treatment of hematologic malignancies.
- Bispecific antibodies: Bispecific antibodies, such as Epcoritamab (Epkinly), offer a novel approach to target multiple antigens on cancer cells.
- Minimal residual disease (MRD): The assessment of MRD is becoming increasingly important in predicting treatment response and overall survival.
The 2024 ASH Annual Meeting isn't just about data, as the duo also offers food recommendations, tourist attractions and fun activities to partake in, as well as interesting facts about San Diego.
This is just a taste of the wealth of information and inspiration waiting at the 2024 ASH Annual Meeting. Check back for future meeting previews with The Show and After Show.
